A Controlled Study of Cognitive Behaviour Therapy with Buspirone or Placebo in Panic Disorder with Agoraphobia

Cottraux, Jean; Note, I D; Cungi, Charly; Légeron, Patrick; Heim, F.; Chneiweiss, L.; Bernard, Geneviève; Bouvard, Martine

doi:10.1192/bjp.167.5.635

Cited by 61 publications

(21 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The combination was superior to psychological therapy alone in the vast majority of studies (Barlow et al 2000;Cottraux et al 1995;de Beurs et al 1995;Gladsjo et al 2001;Marks et al 1993;Mavissakalian and Michelson 1986;Oehrberg et al 1995;Stein et al 2000;Telch et al 1985;Zitrin et al 1980Zitrin et al , 1983, whereas only two studies showed no difference between combined treatment and psychological therapy (Marks et al 1983;Sharp et al 1997). Despite statements implying the opposite, there is no methodologically sound study showing that drugs lessen the gains with CBT.…”

Section: Monoamine Oxidase Inhibitors (Maoi)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: Monoamine Oxidase Inhibitors (Maoi)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

show abstract

“…Expectations were self-rated by a scale used in a previous trial for agoraphobia [34, 35]ranging from 0 (i.e. ‘The treatment will help me a lot’) to 8 (i.e.…”

Section: Methodsmentioning

confidence: 99%

“…Each scale ranged from 0 to 8. This scale was derived from the French version of Marks’s QOL scale for agoraphobia which was used in a previous trial [34, 35]and adapted for social phobia. The higher the scale, the more QOL was impaired.…”

Section: Methodsmentioning

confidence: 99%

Cognitive Behavior Therapy versus Supportive Therapy in Social Phobia: A Randomized Controlled Trial

Cottraux

Note²,

Albuisson³

et al. 2000

Psychother Psychosom

Self Cite

View full text Add to dashboard Cite

Background: The efficacy of cognitive behaviour therapy (CBT) in social phobia has been demonstrated in several controlled trials and meta-analyses, but no comparison of CBT with supportive therapy (ST) can be found in the literature. Method: The aim of the trial was to study the effectiveness of CBT versus ST carried out ‘as usual’. Sixty-seven DSM-4 social phobic patients (89% generalized subtype, most with avoidant personality) were randomly allocated into two groups. Group 1 (CBT) received 8 1-hour sessions of individual cognitive therapy (CT) for 6 weeks, followed by 6 2-hour sessions of social skills training (SST) in group weekly. Group 2 received ST for 12 weeks (6 half-hour sessions), then the patients were switched to CBT. All patients agreed not to take any medication during the whole trial. In group 1, 29 patients reached week 6, 27 reached week 12, and 24 weeks 36 and 60 (endpoint). In group 2, 29 patients reached week 6, 28 reached weeks 12 and 18, 26 week 24, and 23 reached weeks 48 and 72 (endpoint). Results: At week 6, after CT, group 1 was better than group 2 on the main social phobia measure. At week 12, after SST, group 1 was better than group 2 on most of the measures and demonstrated a significantly higher rate of responders. This finding was replicated after switching group 2 to CBT. Sustained improvement was observed in both groups at follow-up. Compliance with abstinence from medication increased over time. Conclusions: CBT was more effective than ST and demonstrated long-lasting effects. This may suggest that social phobia management requires more than a simple and inexpensive psychological intervention.

show abstract

“…The permanency of what is learned in therapy (i.e., skills, behaviors, etc.) is believed to be one of the reasons that the effects of CBT tend to be superior to pharmacological approaches at follow-up assessments (Barlow, Gorman, Shear, & Woods, 2000;Cottraux et al, 1995;de Beurs, van Dyke, Lange, & van Balkom, 1999).…”

mentioning

confidence: 99%

Long-term stability of cognitive behavioral therapy effects for panic disorder with agoraphobia: A two-year follow-up study

Gloster

Hauke

Höfler

et al. 2013

Behaviour Research and Therapy

View full text Add to dashboard Cite

A Controlled Study of Cognitive Behaviour Therapy with Buspirone or Placebo in Panic Disorder with Agoraphobia

Abstract: Buspirone enhanced the effects of cognitive behaviour therapy on generalised anxiety and agoraphobia in the short term.

Cited by 61 publications

References 11 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Cognitive Behavior Therapy versus Supportive Therapy in Social Phobia: A Randomized Controlled Trial

Long-term stability of cognitive behavioral therapy effects for panic disorder with agoraphobia: A two-year follow-up study

Contact Info

Product

Resources

About